查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2065229

精準醫療軟體市場預測至2034年－全球分析（按組件、部署模式、技術、功能、應用、最終用戶和地區分類）

Precision Medicine Software Market Forecasts to 2034 - Global Analysis By Component (Software and Services), Deployment Mode, Technology, Functionality, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球精準醫療軟體市場預計將在 2026 年達到 38 億美元，到 2034 年達到 126 億美元，預測期內複合年成長率為 16.2%。

精準醫療軟體是指一套全面的計算工具和分析平台，旨在透過整合基因組學、蛋白質組學、臨床和環境數據，並將其轉化為可操作的治療方案，從而支援個人化醫療。這些解決方案使醫療專業人員能夠根據患者特異性的分子和基因譜最佳化治療策略，擺脫千篇一律的疾病管理方法。其主要功能包括基因組數據分析、臨床決策支援、生物標記識別、藥物基因體學學建模以及與電子健康記錄的整合。透過利用這些功能，腫瘤學家、研究人員和臨床醫生可以最佳化治療方法的選擇和劑量，從而改善患者的治療效果。

基因測序技術的快速發展和定序成本的降低

過去十年間，次世代定序成本的顯著下降推動了基因組數據的廣泛產生，使得越來越多的醫療機構能夠進行常規臨床定序。隨著基因測序成本的降低，可用於臨床解讀的患者基因組數據量呈指數級成長，這催生了對能夠處理和註釋複雜基因變異並將其轉化為臨床可操作建議的先進軟體平台的日益成長的需求。同時，不斷擴展的藥物基因藥物基因體學資料庫和精準腫瘤學指南為人工智慧驅動的軟體工具提供了科學基礎，這些工具能夠更準確、更可靠地將患者與標靶治療進行匹配。

數據互通性挑戰和分散的醫療保健IT生態系統

精準醫療軟體的有效性本質上取決於其整合來自異質系統的各種資料流的能力，這些資料流包括基因組、臨床、影像和生活方式資訊。現有的醫療保健IT生態系統存在電子健康記錄平台各自獨立、數據標準不相容以及編碼實踐不一致等問題，阻礙了數據的無縫交換。在多中心醫療網路中實施可互通的精準醫療工作流程需要大量的技術投資和組織協調。此外，不同司法管轄區對資料共用法規的不同解讀造成了法律上的複雜性，延緩了大規模基因組資料庫的開發，而這些資料庫對於檢驗人工智慧驅動的臨床決策工具之間重要。

腫瘤學領域對伴隨診斷和標靶治療方案的需求

腫瘤學領域為精準醫療軟體提供了最迫切、最廣泛的商業性機會。這主要得益於分子標靶療法的激增，而這些療法需要伴隨診斷測試來進行患者分層。隨著越來越多的FDA批准的、需要基因生物標記的標靶抗癌藥物問世，能夠解讀腫瘤定序結果並為患者匹配合適治療方法的軟體需求日益成長。基於雲端的基因組分析平台使地方癌症診所能夠獲得以往僅限於大學癌症中心的精準醫療能力，顯著擴大了目標市場，並加速了個人化癌症治療策略的臨床應用。

人工智慧驅動的臨床決策工具相關的法規和標準錯綜複雜，且不斷演變。

整合了人工智慧診斷推薦功能的精準醫療軟體平台正面臨日益嚴格的監管審查，因為監管機構難以在現有的醫療設備框架內對這些新工具進行分類和檢驗。由於缺乏全球統一的人工智慧軟體醫療設備標準，開發商在尋求跨市場商業化策略時面臨合規方面的不確定性。此外，基於非代表性患者群體訓練的人工智慧模型中可能存在的演算法偏差會帶來臨床風險，從而導致監管審查日益嚴格。持續的上市後監測和演算法決策過程的強制性透明度要求加重了合規負擔，並可能阻礙創新步伐。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對精準醫療軟體市場產生了多方面的影響。儘管醫療衛生工作的重點轉向應對疫情造成了短期衝擊，但這場危機也促使各方加速投資基因組基礎設施和數據分析能力建設。 mRNA疫苗的快速研發以及對SARS-CoV-2變異株的基因組監測，充分展現了大規模精準基因組學的強大力量，並提高了政策制定者和醫療衛生管理者對基因組數據平台戰略價值的認知。這種各方對精準醫療基礎建設的重新運作，正推動著疫情後對支持基因組分析、臨床決策支援和人群健康管理的軟體解決方案的持續投資。

在預測期內，軟體領域預計將佔據最大的市場佔有率。

預計在預測期內，軟體領域將佔據最大的市場佔有率。臨床決策支援工具、基因組數據分析平台和基於人工智慧的分析解決方案是該市場的主要收入來源，由於它們在為每位患者提供個人化醫療服務方面發揮直接作用，因此價格居高不下。基因組突變資料庫的持續擴展以及人工智慧在自動化分子腫瘤學委員會支持中的日益普及，都支撐著對軟體的強勁需求。此外，常規的授權模式為主要平台供應商提供了可預測的收入來源，進一步鞏固了軟體領域的領先地位。

預計在預測期內，基於雲端的採用細分市場將呈現最高的複合年成長率。

在預測期內，基於雲端的精準醫療應用領域預計將呈現最高的成長率，這主要得益於雲端平台在管理大規模基因組資料集方面所提供的擴充性、成本效益和協作能力。基於雲端的精準醫療平台能夠實現地理位置分散的臨床站點之間的即時資料共用，支援聯邦學習模型（可在保護資料隱私的同時進行人工智慧訓練），並且無需昂貴的本地基因組運算基礎設施。隨著醫療機構日益重視數位轉型和雲端優先的IT策略，從大規模醫療系統到小規模臨床環境，透過雲端交付的精準醫療軟體的採用正在加速推進。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率。美國在全球精準腫瘤學舉措處於領先地位，這得益於「我們所有人研究計畫」（All of Us Research Program）等突破性計畫以及學術機構和區域癌症中心廣泛採用基因組檢測。主要基因組分析軟體供應商的存在、資金雄厚的生物技術生態系統推動伴隨診斷的發展，以及有利於分子檢測的保險報銷方案，都進一步鞏固了其在該地區市場領先地位。加拿大加大對國家基因組基礎設施的投資，也進一步提升了在北美市場的主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率。中國的國家精準醫療舉措，以及大學附屬醫院次世代定序能力的快速發展，正在催生對基因組分析和臨床決策支援軟體的巨大需求。印度快速成長的製藥和生技產業正在推動精準醫療平台在藥物研發和臨床試驗的應用。韓國和日本也在加速推進國家基因組計畫的投資，為尋求在該地區拓展業務的國內外精準醫療軟體供應商創造了有利環境。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球精準醫療軟體市場：依組件分類

  • 軟體
    • 臨床決策支援軟體
    • 基因組數據分析軟體
    • 電子健康記錄 (EHR) 整合軟體
    • 生物資訊軟體
    • 基於人工智慧和機器學習的平台
  • 服務

第6章 全球精準醫療軟體市場：依部署模式分類

  • 基於雲端的
  • 現場
  • 混合實現

第7章 全球精準醫療軟體市場：依技術分類

  • 人工智慧（AI）
  • 機器學習（ML）
  • 巨量資料分析
  • 生物資訊學
  • 基因測序分析
  • 自然語言處理（NLP）
  • 用於醫療保健數據的區塊鏈

第8章 全球精準醫療軟體市場：功能

  • 資料管理
  • 臨床工作流程管理
  • 團體健康管理
  • 預測分析
  • 基因組分析
  • 最佳化治療方法

第9章 全球精準醫療軟體市場：依應用領域分類

  • 腫瘤學
  • 罕見疾病
  • 心血管疾病
  • 神經病變
  • 感染疾病
  • 藥物基因體學
  • 生殖健康
  • 免疫學
  • 其他用途

第10章 全球精準醫療軟體市場：依最終用戶分類

  • 醫院和診所
  • 診斷檢查室
  • 製藥和生物技術公司
  • 學術研究機構
  • 受託研究機構（CRO）
  • 醫療保健IT公司

第11章 全球精準醫療軟體市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Tempus AI
  • SOPHiA GENETICS
  • IQVIA
  • Foundation Medicine
  • Fabric Genomics
  • PierianDx
  • Syapse
  • Genedata AG
  • Owkin
  • GenomOncology
  • 2bPrecise
  • Illumina
  • QIAGEN
  • Oracle Health
  • Precision Medicine Group
Product Code: SMRC36782

According to Stratistics MRC, the Global Precision Medicine Software Market is accounted for $3.8 billion in 2026 and is expected to reach $12.6 billion by 2034, growing at a CAGR of 16.2% during the forecast period. Precision Medicine Software encompasses a comprehensive suite of computational tools and analytics platforms designed to support individualized patient care by integrating genomic, proteomic, clinical, and environmental data into actionable therapeutic insights. These solutions enable healthcare providers to tailor treatment strategies based on a patient's unique molecular and genetic profile, moving beyond one-size-fits-all approaches to disease management. Core functionalities include genomic data analysis, clinical decision support, biomarker identification, pharmacogenomics modeling, and electronic health record integration, collectively enabling oncologists, researchers, and clinicians to optimize therapeutic selection and dosing for improved patient outcomes.

Market Dynamics:

Driver:

Rapid advances in genomic sequencing technologies and declining sequencing costs

The dramatic reduction in next-generation sequencing costs over the past decade has democratized genomic data generation, enabling routine clinical sequencing across a growing number of healthcare institutions. As genome sequencing becomes financially accessible, the volume of patient genomic data available for clinical interpretation is expanding exponentially, driving demand for sophisticated software platforms capable of processing, annotating, and translating complex genetic variants into clinically actionable recommendations. Simultaneously, expanding pharmacogenomics databases and precision oncology guidelines are providing the scientific foundation for AI-driven software tools that can match patients to targeted therapies with greater accuracy and confidence.

Restraint:

Data interoperability challenges and fragmented health IT ecosystems

The effectiveness of precision medicine software depends fundamentally on its ability to integrate diverse data streams including genomic, clinical, imaging, and lifestyle information from heterogeneous systems. Existing health IT ecosystems are characterized by siloed electronic health record platforms, incompatible data standards, and inconsistent coding practices that impede seamless data exchange. Implementing interoperable precision medicine workflows across multi-site healthcare networks requires substantial technical investment and organizational coordination. Furthermore, varying interpretations of data sharing regulations across jurisdictions create legal complexity that delays the establishment of large-scale genomic databases essential for validating AI-driven clinical decision tools.

Opportunity:

Oncology-driven demand for companion diagnostics and targeted therapy selection

The oncology sector represents the most immediate and expansive commercial opportunity for precision medicine software, driven by the proliferation of molecularly targeted therapies requiring companion diagnostic testing for patient stratification. As the number of FDA-approved targeted oncology drugs with genomic biomarker requirements grows, demand for software capable of interpreting tumor sequencing results and matching patients to applicable therapies is intensifying. Cloud-based genomic interpretation platforms are enabling community oncology practices to access precision medicine capabilities previously confined to academic cancer centers, significantly expanding the addressable market and accelerating clinical implementation of personalized cancer care strategies.

Threat:

Regulatory complexity and evolving standards for AI-based clinical decision tools

Precision medicine software platforms that incorporate AI-driven diagnostic recommendations are subject to heightened regulatory scrutiny as authorities grapple with classifying and validating these novel tools under existing medical device frameworks. The absence of globally harmonized standards for AI software as a medical device creates compliance uncertainty for developers targeting multi-market commercialization strategies. Additionally, the potential for algorithmic bias embedded in AI models trained on non-representative patient populations poses clinical risks that regulators are increasingly scrutinizing. Continuous post-market surveillance requirements and mandatory transparency in algorithmic decision-making represent growing compliance burdens that could constrain innovation velocity.

Covid-19 Impact:

The COVID-19 pandemic generated mixed effects on the Precision Medicine Software market. While short-term disruptions occurred as healthcare priorities shifted toward pandemic management, the crisis also catalyzed accelerated investment in genomics infrastructure and data analytics capabilities. The rapid development of mRNA vaccines and genomic surveillance of SARS-CoV-2 variants demonstrated the power of precision genomics at scale, elevating awareness among policymakers and healthcare executives of the strategic value of genomic data platforms. This renewed institutional commitment to precision medicine infrastructure is translating into sustained post-pandemic investment in software solutions supporting genomic interpretation, clinical decision support, and population health management.

The Software segment is expected to be the largest during the forecast period

The Software segment is expected to account for the largest market share during the forecast period. Clinical decision support tools, genomic data analysis platforms, and AI-based analytics solutions form the revenue backbone of this market, commanding premium pricing given their direct role in enabling personalized patient care. The continuous enrichment of genomic variant databases and the growing adoption of AI for automated molecular tumor board support are sustaining strong software demand. The Software segment's dominance is further reinforced by recurring licensing models that provide predictable revenue streams for leading platform vendors.

The Cloud-Based Deployment segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Cloud-Based Deployment segment is predicted to witness the highest growth rate, driven by the scalability, cost-efficiency, and collaborative capabilities that cloud platforms offer for managing large genomic datasets. Cloud-based precision medicine platforms enable real-time data sharing across geographically dispersed clinical sites, support federated learning models that preserve data privacy while enabling AI training, and eliminate the need for costly on-premise genomic computing infrastructure. As healthcare organizations increasingly prioritize digital transformation and cloud-first IT strategies, adoption of cloud-delivered precision medicine software is accelerating across both large health systems and smaller clinical environments.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share. The United States leads global precision oncology initiatives, supported by landmark programs such as the All of Us Research Program and widespread genomic testing adoption in academic and community oncology centers. The presence of leading genomic analytics software vendors, a well-funded biotech ecosystem driving companion diagnostic development, and favorable reimbursement pathways for molecular testing collectively sustain the region's market leadership. Canada's growing investment in national genomics infrastructure further contributes to North America's dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. China's national precision medicine initiative, coupled with rapidly expanding next-generation sequencing capacity across academic hospitals, is generating substantial demand for genomic interpretation and clinical decision support software. India's growing pharmaceutical and biotechnology sector is driving adoption of precision medicine platforms for drug discovery and clinical trial applications. South Korea and Japan are also accelerating investment in national genomics programs, creating fertile ground for international and domestic precision medicine software vendors seeking to expand their presence across the region.

Key players in the market

Some of the key players in Global Precision Medicine Software Market include Tempus AI, SOPHIA GENETICS, IQVIA, Foundation Medicine, Fabric Genomics, PierianDx, Syapse, Genedata AG, Owkin, GenomOncology, 2bPrecise, Illumina, QIAGEN, Oracle Health, and Precision Medicine Group.

Key Developments:

In January 2026, Tempus AI announced the expansion of its Lens genomic data analytics platform with new multi-omic integration capabilities, enabling simultaneous analysis of genomic, transcriptomic, and proteomic data within a unified clinical reporting interface. The enhanced platform supports oncologists in identifying complex biomarker patterns predictive of treatment response, advancing the company's position in AI-driven precision oncology decision support.

In February 2026, SOPHIA GENETICS announced a strategic collaboration with a leading European healthcare network to deploy its SOPHiA DDM platform across multiple cancer centers, standardizing molecular tumor board workflows and genomic interpretation protocols. The partnership aims to harmonize precision medicine practices across the network, enabling real-time data sharing and accelerating the adoption of evidence-based targeted therapy selection for cancer patients.

Components Covered:

  • Software
  • Services

Deployment Modes Covered:

  • Cloud-Based
  • On-Premise
  • Hybrid Deployment

Technologies Covered:

  • Artificial Intelligence (AI)
  • Machine Learning (ML)
  • Big Data Analytics
  • Bioinformatics
  • Genomic Sequencing Analytics
  • Natural Language Processing (NLP)
  • Blockchain for Healthcare Data

Functionalities Covered:

  • Data Management
  • Clinical Workflow Management
  • Population Health Management
  • Predictive Analytics
  • Genomic Interpretation
  • Therapy Optimization

Applications Covered:

  • Oncology
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious Diseases
  • Pharmacogenomics
  • Reproductive Health
  • Immunology
  • Other Applications

End Users Covered:

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutes
  • Contract Research Organizations (CROs)
  • Healthcare IT Companies

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Precision Medicine Software Market, By Component

  • 5.1 Software
    • 5.1.1 Clinical Decision Support Software
    • 5.1.2 Genomic Data Analysis Software
    • 5.1.3 Electronic Health Record (EHR) Integration Software
    • 5.1.4 Bioinformatics Software
    • 5.1.5 AI & Machine Learning-Based Platforms
  • 5.2 Services

6 Global Precision Medicine Software Market, By Deployment Mode

  • 6.1 Cloud-Based
  • 6.2 On-Premise
  • 6.3 Hybrid Deployment

7 Global Precision Medicine Software Market, By Technology

  • 7.1 Artificial Intelligence (AI)
  • 7.2 Machine Learning (ML)
  • 7.3 Big Data Analytics
  • 7.4 Bioinformatics
  • 7.5 Genomic Sequencing Analytics
  • 7.6 Natural Language Processing (NLP)
  • 7.7 Blockchain for Healthcare Data

8 Global Precision Medicine Software Market, By Functionality

  • 8.1 Data Management
  • 8.2 Clinical Workflow Management
  • 8.3 Population Health Management
  • 8.4 Predictive Analytics
  • 8.5 Genomic Interpretation
  • 8.6 Therapy Optimization

9 Global Precision Medicine Software Market, By Application

  • 9.1 Oncology
  • 9.2 Rare Diseases
  • 9.3 Cardiovascular Diseases
  • 9.4 Neurological Disorders
  • 9.5 Infectious Diseases
  • 9.6 Pharmacogenomics
  • 9.7 Reproductive Health
  • 9.8 Immunology
  • 9.9 Other Applications

10 Global Precision Medicine Software Market, By End User

  • 10.1 Hospitals and Clinics
  • 10.2 Diagnostic Laboratories
  • 10.3 Pharmaceutical & Biotechnology Companies
  • 10.4 Academic & Research Institutes
  • 10.5 Contract Research Organizations (CROs)
  • 10.6 Healthcare IT Companies

11 Global Precision Medicine Software Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Tempus AI
  • 14.2 SOPHiA GENETICS
  • 14.3 IQVIA
  • 14.4 Foundation Medicine
  • 14.5 Fabric Genomics
  • 14.6 PierianDx
  • 14.7 Syapse
  • 14.8 Genedata AG
  • 14.9 Owkin
  • 14.10 GenomOncology
  • 14.11 2bPrecise
  • 14.12 Illumina
  • 14.13 QIAGEN
  • 14.14 Oracle Health
  • 14.15 Precision Medicine Group

List of Tables

  • Table 1 Global Precision Medicine Software Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Precision Medicine Software Market Outlook, By Component (2023-2034) ($MN)
  • Table 3 Global Precision Medicine Software Market Outlook, By Software (2023-2034) ($MN)
  • Table 4 Global Precision Medicine Software Market Outlook, By Clinical Decision Support Software (2023-2034) ($MN)
  • Table 5 Global Precision Medicine Software Market Outlook, By Genomic Data Analysis Software (2023-2034) ($MN)
  • Table 6 Global Precision Medicine Software Market Outlook, By Electronic Health Record (EHR) Integration Software (2023-2034) ($MN)
  • Table 7 Global Precision Medicine Software Market Outlook, By Bioinformatics Software (2023-2034) ($MN)
  • Table 8 Global Precision Medicine Software Market Outlook, By AI & Machine Learning-Based Platforms (2023-2034) ($MN)
  • Table 9 Global Precision Medicine Software Market Outlook, By Services (2023-2034) ($MN)
  • Table 10 Global Precision Medicine Software Market Outlook, By Deployment Mode (2023-2034) ($MN)
  • Table 11 Global Precision Medicine Software Market Outlook, By Cloud-Based (2023-2034) ($MN)
  • Table 12 Global Precision Medicine Software Market Outlook, By On-Premise (2023-2034) ($MN)
  • Table 13 Global Precision Medicine Software Market Outlook, By Hybrid Deployment (2023-2034) ($MN)
  • Table 14 Global Precision Medicine Software Market Outlook, By Technology (2023-2034) ($MN)
  • Table 15 Global Precision Medicine Software Market Outlook, By Artificial Intelligence (AI) (2023-2034) ($MN)
  • Table 16 Global Precision Medicine Software Market Outlook, By Machine Learning (ML) (2023-2034) ($MN)
  • Table 17 Global Precision Medicine Software Market Outlook, By Big Data Analytics (2023-2034) ($MN)
  • Table 18 Global Precision Medicine Software Market Outlook, By Bioinformatics (2023-2034) ($MN)
  • Table 19 Global Precision Medicine Software Market Outlook, By Genomic Sequencing Analytics (2023-2034) ($MN)
  • Table 20 Global Precision Medicine Software Market Outlook, By Natural Language Processing (NLP) (2023-2034) ($MN)
  • Table 21 Global Precision Medicine Software Market Outlook, By Blockchain for Healthcare Data (2023-2034) ($MN)
  • Table 22 Global Precision Medicine Software Market Outlook, By Functionality (2023-2034) ($MN)
  • Table 23 Global Precision Medicine Software Market Outlook, By Data Management (2023-2034) ($MN)
  • Table 24 Global Precision Medicine Software Market Outlook, By Clinical Workflow Management (2023-2034) ($MN)
  • Table 25 Global Precision Medicine Software Market Outlook, By Population Health Management (2023-2034) ($MN)
  • Table 26 Global Precision Medicine Software Market Outlook, By Predictive Analytics (2023-2034) ($MN)
  • Table 27 Global Precision Medicine Software Market Outlook, By Genomic Interpretation (2023-2034) ($MN)
  • Table 28 Global Precision Medicine Software Market Outlook, By Therapy Optimization (2023-2034) ($MN)
  • Table 29 Global Precision Medicine Software Market Outlook, By Application (2023-2034) ($MN)
  • Table 30 Global Precision Medicine Software Market Outlook, By Oncology (2023-2034) ($MN)
  • Table 31 Global Precision Medicine Software Market Outlook, By Rare Diseases (2023-2034) ($MN)
  • Table 32 Global Precision Medicine Software Market Outlook, By Cardiovascular Diseases (2023-2034) ($MN)
  • Table 33 Global Precision Medicine Software Market Outlook, By Neurological Disorders (2023-2034) ($MN)
  • Table 34 Global Precision Medicine Software Market Outlook, By Infectious Diseases (2023-2034) ($MN)
  • Table 35 Global Precision Medicine Software Market Outlook, By Pharmacogenomics (2023-2034) ($MN)
  • Table 36 Global Precision Medicine Software Market Outlook, By Reproductive Health (2023-2034) ($MN)
  • Table 37 Global Precision Medicine Software Market Outlook, By Immunology (2023-2034) ($MN)
  • Table 38 Global Precision Medicine Software Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 39 Global Precision Medicine Software Market Outlook, By End User (2023-2034) ($MN)
  • Table 40 Global Precision Medicine Software Market Outlook, By Hospitals and Clinics (2023-2034) ($MN)
  • Table 41 Global Precision Medicine Software Market Outlook, By Diagnostic Laboratories (2023-2034) ($MN)
  • Table 42 Global Precision Medicine Software Market Outlook, By Pharmaceutical & Biotechnology Companies (2023-2034) ($MN)
  • Table 43 Global Precision Medicine Software Market Outlook, By Academic & Research Institutes (2023-2034) ($MN)
  • Table 44 Global Precision Medicine Software Market Outlook, By Contract Research Organizations (CROs) (2023-2034) ($MN)
  • Table 45 Global Precision Medicine Software Market Outlook, By Healthcare IT Companies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) are also represented in the same manner as above.